Clinical trials: Post-transplant Hepatitis C
Chronic Hepatitis C
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
The primary objective of this program is to provide DCV for 24 weeks to be given in combination with SOF to subjects with chronic hepatitis C with decompensated cirrhosis or post-liver transplant subjects with chronic hepatitis C…
- Trial name
- NCT02161939
- Testing
- Daclatasvir (BMS-790052), Sofosbuvir
- Where
- 20 sites in United States
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon plus ribavirin, will clear hepatitis C virus (HCV) RNA from the blood in HCV-infected recipients and reduce the risk of recurrent HCV…
- Trial name
- LADR (NCT00135798)
- Testing
- LADR Treatment
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Transplantation, Hepatitis C
Treatment of Recurrent Hepatitis C After Liver Transplantation
In France, 50% of the hepatitis C virus carriers develop chronic clinical hepatitis, which may lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is constant after transplantation.
- Trial name
- TRANSPEG (NCT00151580)
- Testing
- Ribavirin
- Where
- 16 sites in France
- Volunteers
- 200 people
- Sponsor
- Rennes University Hospital
Hepatitis C
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
This trial was open to participants who had received a liver transplant or had cirrhosis due to chronic HCV. All subjects were treated with daclatasvir+sofosbuvir+ribavirin and were followed for 24 weeks post treatment.
- Trial name
- ALLY 1 (NCT02032875)
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 5 sites in United States
- Volunteers
- 116 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Renal Insufficiency, Chronic
HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated…
- Conditions
- Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney
- Trial name
- NCT02902120
- Testing
- Post-transplant Grazoprevir and Elbasvir
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Chronic HCV Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
This study will evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) in participants with advanced liver disease or posttransplant and chronic genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02010255
- Testing
- LDV/SOF, RBV
- Where
- 34 sites in Australia, Austria and 10 more
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Hepatitis C
Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
End stage HCV-related cirrhosis has become a major indication for liver transplantation (LT). Unfortunately, recurrence of HCV infection on the liver graft occurs in almost all patients following transplantation and causes a…
- Trial name
- NCT00638144
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Liver Transplantation
Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation
An open-label randomized multicenter clinical study comparing three regimes of immunosuppression : (A) tacrolimus and steroids, (B) antithymocyte induction therapy and full dose of tacrolimus, (C) antithymocyte induction therapy…
- Trial name
- BEFIRTH (NCT00538265)
- Testing
- tacrolimus, tacrolimus, ATG, ATG+mycophénolate mofétil+tacrolimus
- Where
- 8 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
Liver Transplantation, Hepatitis C
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation
The main objective of this study is to assess whether a recently-developed bioassay for the molecule "secreted fibrinogen-like protein 2" (sFGL2) can be used to predict the recurrence and/or progression of Hepatitis C Virus…
- Trial name
- NCT00701272
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University Health Network, Toronto
Hepatitis C Viral Infection
Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)
The study is a single centre, single arm, open-label, proof of concept study enrolling 20 adult primary liver transplant recipients with genotype 1 HCV infection.
- Trial name
- NCT02478229
- Testing
- Sofosbuvir (SOF) and Ledipasvir (LDV)
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Liver Transplantation
Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation
Background and Aim: The immunosuppression influence on the response to antiviral therapy (AVT) for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients remains controversial, especially for the rarely…
- Trial name
- NCT03665766
- Testing
- Cycloserine,Tacrolimus
- Volunteers
- 126 people
- Sponsor
- Ain Shams University
Hepatitis C
Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation
The purpose of this study is to evaluate the effect of cyclosporine, an anti-rejection drug, on the clearance of the hepatitis C virus in liver transplant subjects being treated with peg-interferon and ribavirin.
- Trial name
- NCT00821587
- Testing
- Cyclosporine, Tacrolimus
- Volunteers
- 39 people
- Sponsor
- University of Florida
Liver Disease
Role of Tissue C4d in Differentiation Between Acut e Rejection and HCV Recurrence After Liver Transplantation
Assessment of the role of tissue C4d complement fragments in liver biopsy as a new marker for differentiating between acute rejection and Hepatitis C (HCV) recurrence in recipients post living donor liver transplantation (LDLT)…
- Trial name
- NCT02209675
- Testing
- liver biopsy
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Ain Shams University
Liver Transplant, Hepatitis C
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver.
- Trial name
- NCT00260208
- Testing
- Cyclosporine A, Tacrolimus
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 361 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C
A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
Patients who are Hepatitis C Negative (HCV negative) and are on the waiting list for a lung transplant at NYULH who consent to participate in this study will receive a lung transplant from a deceased donor that is HCV positive.
- Trial name
- NCT03523871
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Recurrent Chronic Hepatitis C Virus, Post Liver Transplant
Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
This is an open-label, single-arm study of sofosbuvir (GS-7977) and ribavirin (RBV) in adults who have had a liver transplant which has become re-infected with hepatitis C.
- Trial name
- NCT01687270
- Testing
- Sofosbuvir, RBV
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
HCV Recurrence, Liver Transplantation
Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection
The purpose of this study is to evaluate the efficacy, safety and tolerability of direct-acting antivirals therapy in liver transplanted patients who experienced HCV recurrence.
- Conditions
- HCV Recurrence, Liver Transplantation, Direct-acting Antiviral Agents
- Trial name
- ANRSCO23CUPILT (NCT01944527)
- Where
- France
- Volunteers
- 699 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Hepatitis C
Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
The purpose of this study is to determine if the administration of a poorly-absorbable antibiotic (rifaximin) for the first three months after liver transplant will reduce the amount of fibrosis (or scarring of the liver) in…
- Trial name
- Rifaximin (NCT01603108)
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Columbia University